| Bibliographic Citation
| - Ghesquieres Hervé, Obéric Lucie, Morschhauser Franck, Tilly Herve, Ribrag Vincent, Lamy Thierry, Thieblemont Catherine, Maisonneuve Herve Gerard, Gressin Remy, Bouabdallah Krimo, Haioun Corinne, Damaj Gandhi, Fornecker Luc-Matthieu, Bouabdallah Reda, Feugier Pierre, Sibon David, Cartron Guillaume, Bonnet Christophe, ANDRÉ Marc, Chartier Loic, Ruminy Philippe, Kraeber-Bodere F, Bodet-Milin C, Berriolo-Riedinger Alina, Briere Josette, Jais Jean-Philippe, Molina Thierry, Itti Emmanuel, Casasnovas Olivier. Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood, American Society of Hematology, 2020, ⟨10.1182/blood.2020008750⟩
- Ghesquieres Hervé, Obéric Lucie, Morschhauser Franck, Tilly Herve, Ribrag Vincent, Lamy Thierry, Thieblemont Catherine, Maisonneuve Herve Gerard, Gressin Remy, Bouabdallah Krimo, Haioun Corinne, Damaj Gandhi, Fornecker Luc-Matthieu, Bouabdallah Reda, Feugier Pierre, Sibon David, Cartron Guillaume, Bonnet Christophe, ANDRÉ Marc, Chartier Loic, Ruminy Philippe, Kraeber-Bodere F, Bodet-Milin C, Berriolo-Riedinger Alina, Briere Josette, Jais Jean-Philippe, Molina Thierry, Itti Emmanuel, Casasnovas Olivier. Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood, American Society of Hematology, 2020, 137 (17), pp.2307-2320. ⟨10.1182/blood.2020008750⟩
- Ghesquieres Hervé, Obéric Lucie, Morschhauser Franck, Tilly Herve, Ribrag Vincent, Lamy Thierry, Thieblemont Catherine, Maisonneuve Herve Gerard, Gressin Remy, Bouabdallah Krimo, Haioun Corinne, Damaj Gandhi, Fornecker Luc-Matthieu, Bouabdallah Reda, Feugier Pierre, Sibon David, Cartron Guillaume, Bonnet Christophe, ANDRÉ Marc, Chartier Loic, Ruminy Philippe, Kraeber-Bodere F, Bodet-Milin C, Berriolo-Riedinger Alina, Briere Josette, Jais Jean-Philippe, Molina Thierry, Itti Emmanuel, Casasnovas Olivier. Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood, American Society of Hematology, 2021, 137 (17), pp.2307-2320. ⟨10.1182/blood.2020008750⟩
- Ghesquieres Hervé, Obéric Lucie, Morschhauser Franck, Tilly Herve, Ribrag Vincent, Lamy Thierry, Thieblemont Catherine, Maisonneuve Herve Gerard, Gressin Remy, Bouabdallah Krimo, Haioun Corinne, Damaj Gandhi, Fornecker Luc-Matthieu, Bouabdallah Reda, Feugier Pierre, Sibon David, Cartron Guillaume, Bonnet Christophe, André Marc, Chartier Loic, Ruminy Philippe, Kraeber-Bodere F, Bodet-Milin C, Berriolo-Riedinger Alina, Briere Josette, Jais Jean-Philippe, Molina Thierry, Itti Emmanuel, Casasnovas Olivier . Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA . Blood, 2021, 137 (17), pp.2307-2320 . ⟨10.1182/blood.2020008750⟩
- Ghesquieres Hervé, Obéric Lucie, Morschhauser Franck, Tilly Herve, Ribrag Vincent, Lamy Thierry, Thieblemont Catherine, Maisonneuve Herve Gerard, Gressin Remy, Bouabdallah Krimo, Haioun Corinne, Damaj Gandhi, Fornecker Luc-Matthieu, Bouabdallah Reda, Feugier Pierre, Sibon David, Cartron Guillaume, Bonnet Christophe, André Marc, Chartier Loic, Ruminy Philippe, Kraeber-Bodere F, Bodet-Milin C, Berriolo-Riedinger Alina, Briere Josette, Jais Jean-Philippe, Molina Thierry, Itti Emmanuel, Casasnovas Olivier. Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA. Blood, 2021, 137 (17), pp.2307-2320. ⟨10.1182/blood.2020008750⟩
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
